We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+12.38%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$4.12B
AUM Growth
+$545M
Cap. Flow
+$493M
Cap. Flow %
11.96%
Top 10 Hldgs %
48.24%
Holding
158
New
26
Increased
23
Reduced
71
Closed
24

Top Buys

Rank Stock Value
1
KLRS
Kalaris Therapeutics
KLRS
+$69M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$68.4M
3
BEKE icon
KE Holdings
BEKE
+$43.5M
4
IGMS
IGM Biosciences
IGMS
+$40.8M
5
ITOS
iTeos Therapeutics
ITOS
+$29.4M

Top Sells

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$42.9M
2
PYPL icon
PayPal
PYPL
+$34.8M
3
AVTR icon
Avantor
AVTR
+$34M
4
ARGX icon
argenx
ARGX
+$30.2M
5
Z icon
Zillow
Z
+$22.1M

Sector Composition

Rank Sector Weight
1 Healthcare 57.47%
2 Consumer Discretionary 10.25%
3 Technology 2.5%
4 Real Estate 1.29%
5 Materials 0.75%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RPTX
51
DELISTED
Repare Therapeutics
RPTX
$17.5M 0.43%
570,000
-30,000
-5% -$794K
RLAY icon
52
Relay Therapeutics
RLAY
$4B
$17M 0.41%
+400,000
New +$15.3M
KURA icon
53
Kura Oncology
KURA
$793M
$16.8M 0.41%
549,100
-28,900
-5% -$638K
DHR icon
54
Danaher
DHR
$138B
$16.1M 0.39%
+84,600
New +$15M
REPL icon
55
Replimune Group
REPL
$454M
$16.1M 0.39%
700,000
-50,000
-7% -$1.14M
KYNB
56
Kyntra Bio
KYNB
$27.4M
$15.6M 0.38%
15,200
-800
-5% -$861K
BBIO icon
57
BridgeBio Pharma
BBIO
$16.4B
$15M 0.36%
400,000
-200,000
-33% -$6.29M
TECH icon
58
Bio-Techne
TECH
$11.2B
$14.9M 0.36%
240,000
-20,000
-8% -$1.3M
IMUX icon
59
Immunic
IMUX
$178M
$14.9M 0.36%
80,000
+20,000
+33% +$3.28M
GM icon
60
CALL
General Motors
GM
$80.9B
$14.8M 0.36%
500,000
– –
AUPH icon
61
Aurinia Pharmaceuticals
AUPH
$1.95B
$14.7M 0.36%
1,000,000
+100,000
+11% +$1.45M
OVID icon
62
Ovid Therapeutics
OVID
$427M
$14.3M 0.35%
+2,500,000
New +$16.7M
DNLI icon
63
Denali Therapeutics
DNLI
$3.79B
$14.3M 0.35%
400,000
-50,000
-11% -$1.51M
FOLD
64
CALL
DELISTED
Amicus Therapeutics
FOLD
$14.1M 0.34%
1,000,000
– –
HARP
65
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$13.6M 0.33%
80,000
-10,000
-11% -$1.44M
SAGE
66
DELISTED
Sage Therapeutics
SAGE
$13.6M 0.33%
222,300
-11,700
-5% -$593K
SWTX
67
DELISTED
SpringWorks Therapeutics
SWTX
$13.6M 0.33%
285,000
-15,000
-5% -$639K
MTCR
68
DELISTED
Metacrine, Inc. Common Stock
MTCR
$13.4M 0.32%
+1,309,513
New +$13.4M
IOVA icon
69
Iovance Biotherapeutics
IOVA
$2.04B
$13.2M 0.32%
400,000
-100,000
-20% -$3.07M
CRDF icon
70
Cardiff Oncology
CRDF
$63M
$12.8M 0.31%
+900,000
New +$5.94M
EPZM
71
DELISTED
Epizyme, Inc
EPZM
$11.9M 0.29%
1,000,000
-875,000
-47% -$11.7M
BMRN icon
72
CALL
BioMarin Pharmaceuticals
BMRN
$11.9B
$11.4M 0.28%
+150,000
New +$15.2M
RNAC icon
73
Cartesian Therapeutics
RNAC
$218M
$11.2M 0.27%
150,000
+53,333
+55% +$4.09M
CYCN icon
74
Cyclerion Therapeutics
CYCN
$15.2M
$11.1M 0.27%
90,879
-1,200
-1% -$137K
YMAB
75
DELISTED
Y-mAbs Therapeutics
YMAB
$10.9M 0.27%
285,028
-15,002
-5% -$597K
1 2
3
4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q3 2020 Portfolio in Review

As of Q3 2020, Artal Group held 158 positions worth $4.12B, up 15% from $3.57B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Artal Group deployed $493M of net new capital in Q3 2020, opening 26 new positions and adding to 23 existing holdings. Its largest new stake was Kalaris Therapeutics: 101,016 shares worth $63.9M.

By sector, the portfolio is most concentrated in Healthcare at 57% of assets, down from 62% a quarter earlier, followed by Consumer Discretionary and Technology.

On the sell side, the largest reduction was argenx, an estimated $30.2M trimmed.

  • Artal Group's largest Q3 2020 buy was Kalaris Therapeutics: 101,016 shares worth $63.9M.
  • Artal Group added most to Agenus in Q3 2020, an estimated $16.1M increase.
  • Artal Group's biggest Q3 2020 reduction was argenx, cutting an estimated $30.2M.
  • Artal Group fully exited Blueprint Medicines in Q3 2020, selling an estimated $42.9M.
  • Artal Group's ten largest holdings make up 48% of its $4.12B portfolio in Q3 2020.
  • Artal Group opened 26 new positions and closed 24 in Q3 2020.
  • Artal Group's portfolio value rose 15% quarter-over-quarter to $4.12B.

Based on Artal Group's 13F filing for Q3 2020, filed 13 Nov 2020.